INMB (INmune Bio) Other Operating Expense: $0.00 Mil (TTM As of Mar. 2026)


INMB INmune Bio Inc INMB
52 GF Score
Price $1.94
GF Value $1.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is INmune Bio Other Operating Expense?

INmune Bio INMB +8.38% 52 Other Operating Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.82 (Fairly Valued). The stock has 5 warning signs investors should review.

INmune Bio's Other Operating Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

INmune Bio's quarterly Other Operating Expense declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

INmune Bio's annual Other Operating Expense increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

INmune Bio Other Operating Expense Historical Data

* Premium members only.

The historical data trend for INmune Bio's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio Other Operating Expense Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

INmune Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INMB
52GF Score
INmune Bio Inc INMB
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

INmune Bio Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.00 Mil mean?
INmune Bio (INMB) has a Other Operating Expense of $0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on INmune Bio and its competitors.
Is INmune Bio's Other Operating Expense too high?
INmune Bio's current Other Operating Expense is $0.00 Mil. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Other Operating Expense compare to GRCE and NTRB?
INmune Bio's Other Operating Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on INmune Bio and its competitors. INmune Bio's current Other Operating Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.94 — trading 6.6% above its estimated fair value. The current Other Operating Expense is $0.00 Mil. INmune Bio's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For INmune Bio (INMB), the current Other Operating Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be overvalued. The current stock price of $1.94 is trading 6.6% above its estimated GF Value™ of $1.82. GuruFocus considers INmune Bio to be Fairly Valued.

Key valuation signals for INMB:

  • Other Operating Expense: $0.00 Mil
  • GF Value™: $1.82 vs. price of $1.94 (6.6% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score

Get the complete analysis for INMB

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.94
Price
$1.82
GF Value